Author:
Josephs Debra,Hutson Thomas E.,Cowey Charles L.,Pickering Lisa M.,Larkin James M.,Gore Martin E.,Van Hemelrijck Mieke,McDermott David F.,Powles Thomas,Chowdhury Paramit,Karapetis Chris,Harper Peter G.,Choueiri Toni K.,Chowdhury Simon
Reference19 articles.
1. Global Cancer Statistics, 2002;Parkin;CA Cancer J Clin,2005
2. Sunitinib versus intereron alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007
3. Pfizer Laboratories Sutent® Sunitinib Maleate Capsules 2006 http://www.pfizer.com/files/products/uspi_sutent.pdf
4. Goddard J Harris K Turner N Chronic Kidney Disease eGuide 2009 http://www.renal.org/whatwedo/InformationResources/CKDeGUID.aspx
5. Safety and efficacy analysis of sunitinib, bevacizumab, and m-TOR inhibitors in metastatic renal cell cancer patients with renal insufficiency;Gupta;J Clin Oncol,2009
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献